Buy & Sell State Street Technology Select Sector SPDR ETF (XLK) – State Street Technology Select Sector SPDR ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Sector/ThematicSector
- -9.21%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 21 daysTypical Hold Time
Over the past 52 weeks, State Street Technology Select Sector SPDR ETF has traded between a low of $119.59 and a high of $198.21, highlighting its annual price range. Over the past three months, State Street Technology Select Sector SPDR ETF has recorded a drawdown of -9.21%, reflecting recent price volatility. On average, investors hold State Street Technology Select Sector SPDR ETF for approximately 21 days, indicating typical investor behavior on the platform.
About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Most Recent News
Gilead and Merck halt lung cancer trial but report positive HIV drug Phase 3 results.
Gilead Sciences and Merck have stopped their Phase 3 trial combining Trodelvy and Keytruda for metastatic non-small cell lung cancer after it failed to show statistically significant benefits. However, they announced positive Phase 3 results for a ne...

American Airlines signs largest sustainable aviation fuel deal with Google, boosting stock.
American Airlines has signed the largest sustainable aviation fuel (SAF) certificate agreement with Google, securing 35 million gallons of SAF over three years to reduce nearly 300,000 metric tons of CO₂ emissions. This deal supports American Airline...

Over 29 pharma firms advance 35+ Treg cell therapies, promising new treatments for autoimmune and transplant diseases.
The Treg cell-based therapies pipeline is robust with more than 29 pharmaceutical companies developing over 35 therapies targeting autoimmune diseases, graft-versus-host disease, and transplant rejection. Key players like Orca Bio, Cellenkos, and Que...
